These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 8677861)

  • 1. The role of neurohormonal activation in chronic heart failure and postmyocardial infarction.
    Sigurdsson A; Swedberg K
    Am Heart J; 1996 Jul; 132(1 Pt 2 Su):229-34. PubMed ID: 8677861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
    Sigurdsson A
    Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.
    Kjaer A; Hesse B
    Clin Physiol; 2001 Nov; 21(6):661-72. PubMed ID: 11722473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ACE inhibition on neurohormones.
    Remme WJ
    Eur Heart J; 1998 Sep; 19 Suppl J():J16-23. PubMed ID: 9796836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure.
    Packer M; Lee WH; Kessler PD; Gottlieb SS; Bernstein JL; Kukin ML
    Circulation; 1987 May; 75(5 Pt 2):IV80-92. PubMed ID: 2882867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurohormonal factors in heart failure. II].
    Cosín Aguilar J; Cruz Fernández JM; de Teresa Galván E; Ferreira Montero IJ; López-Sendón J; Soler Soler J; Tamargo Menéndez J
    Rev Esp Cardiol; 1996 May; 49(5):317-27. PubMed ID: 8744385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and long-term neurohormonal activation following acute myocardial infarction.
    Sigurdsson A; Held P; Swedberg K
    Am Heart J; 1993 Nov; 126(5):1068-76. PubMed ID: 8237747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
    Yan RT; White M; Yan AT; Yusuf S; Rouleau JL; Maggioni AP; Hall C; Latini R; Afzal R; Floras J; Masson S; McKelvie RS;
    Am J Cardiol; 2005 Sep; 96(5):698-704. PubMed ID: 16125499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New concepts in post-infarction ventricular remodeling.
    Udelson JE; Patten RD; Konstam MA
    Rev Cardiovasc Med; 2003; 4 Suppl 3():S3-12. PubMed ID: 14564229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R; McMurray JJ
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine changes in acute myocardial infarction.
    McAlpine HM; Cobbe SM
    Am J Med; 1988 Mar; 84(3A):61-6. PubMed ID: 3064600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology.
    Pinto YM; de Smet BG; van Gilst WH; Scholtens E; Monnink S; de Graeff PA; Wesseling H
    Cardiovasc Res; 1993 Nov; 27(11):1933-8. PubMed ID: 8287399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is neurohormonal activation a major determinant of the response to ACE inhibition in left ventricular dysfunction and heart failure?
    Sigurdsson A; Swedberg K
    Br Heart J; 1994 Sep; 72(3 Suppl):S75-80. PubMed ID: 7946809
    [No Abstract]   [Full Text] [Related]  

  • 17. The treatment of heart failure: the role of neurohumoral activation.
    Middlekauff HR; Mark AL
    Intern Med; 1998 Feb; 37(2):112-22. PubMed ID: 9550589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction.
    Beckwith C; Munger MA
    Ann Pharmacother; 1993 Jun; 27(6):755-66. PubMed ID: 8329800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Heart failure after myocardial infarction: diagnosis, treatment, prevention. Echocardiography should be a routine procedure in myocardial infarction].
    Willenheimer R; Erhardt L; Eskilsson J
    Lakartidningen; 1998 Jul; 95(28-29):3183-7. PubMed ID: 9700263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart failure, ventricular remodelling and the renin-angiotensin system: insights from recently completed clinical trials.
    Young JB
    Eur Heart J; 1993 Jul; 14 Suppl C():14-7. PubMed ID: 8365422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.